First-line lenvatinib + pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study Meeting Abstract
| Authors: | Lee, C. H.; Gurney, H.; Atduev, V.; Suárez, C.; Climent Duran, M. A.; Pook, D. W.; Tomczak, P.; Barthelemy, P.; Lee, J. L.; Nalbandian, T.; Stus, V.; Ferguson, T.; Wiechno, P.; Gokmen, E.; Lacombe, L.; Gedye, C.; Burgents, J.; Sharma, M.; Peng, X.; Albiges, L. |
| Abstract Title: | First-line lenvatinib + pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.4518 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: 4518 -- This meeting was also held virtually -- Source: Cinahl |
